AMR Surveillance Has Moved Forward, But the Next Phase Will Be Harder to Fund
Nearly 10 years of Fleming Fund activity produced clear gains in AMR surveillance across low- and middle-income countries, yet the most important message from this synthesis is not simply that progress happened. It is that surveillance now has to be designed for endurance. The paper pulls together lessons from people who worked within and alongside the Fleming Fund across different organizations and regions, using four virtual workshops, multiple manuscript drafts, and consensus-building across a broad writing group that included senior scientists, clinicians, and experts in public, animal, environment, and food sciences health.
The practical implication is direct: surveillance systems cannot rely on expansion alone. They have to be sharpened.
What the Fleming Fund Experience Says About Surveillance Design
This synthesis places surveillance where it belongs in the antimicrobial resistance response: not as a background reporting exercise, but as an operational tool that informs action. Over time, the Fleming Fund achieved significant improvements in AMR surveillance, and the paper treats those gains as evidence that investment can shift national capability when systems are built with enough technical support and institutional coordination.
The most durable lesson is that surveillance works best when it is positioned to answer specific policy and clinical questions. Broad data collection may be attractive in theory, but in settings with limited budgets, staffing constraints, and uneven infrastructure, unfocused surveillance can drain effort without producing information that changes practice. A leaner system with a sharper scope, defined frequency, and appropriate depth of data is more likely to influence treatment policy, laboratory planning, and national stewardship priorities.
This is where the biology and the bureaucracy meet. AMR evolves through selection pressure, transmission, and local prescribing patterns, so surveillance has to be quick enough and precise enough to detect shifts before resistance becomes embedded in routine care. If data arrive too late, or if the system is too diffuse to be trusted, clinicians and ministries are left reacting to problems that have already hardened into standard practice.
Funding Gaps Will Shape Whether Current Capacity Survives
The synthesis is candid about what happens after donor-backed momentum slows. Sustaining AMR surveillance will require expanded domestic public financing, larger-scale private sector engagement, or stronger multilateral support. Without one or more of those streams, the gains achieved over the past decade risk plateauing or eroding.
One sentence captures the tension plainly: recent progress is real, but it is not self-sustaining.
That reality matters because surveillance systems are not one-time projects. They depend on laboratories, data systems, trained staff, specimen transport, quality assurance, and governance structures that must be maintained year after year. Even modest interruptions can weaken the chain between case detection and national response. In countries where health budgets are already stretched, AMR surveillance may be forced to compete with acute care, maternal health, outbreaks, and other urgent priorities. The paper argues for investment models that protect current capacity while allowing further strengthening, rather than demanding unrealistic leaps in capability.
Country-Led Systems Need Simpler Architecture and Better Alignment
A recurring theme in the synthesis is the importance of country-led approaches. The future of surveillance depends on systems that are not just externally supported, but locally owned and operationally realistic. Architecture matters here. If surveillance platforms are too complex, too costly to run, or too dependent on foreign technical scaffolding, they become fragile once donor attention shifts.
The paper calls for technical and architectural developments that streamline investment and financing. In practice, that means building systems that can be maintained with available workforce and infrastructure, rather than systems that look optimal on paper but fail under local constraints. It also means aligning surveillance with country priorities so the data collected are directly useful to ministries of health, agriculture, and environment, rather than producing reports with limited bedside or policy value.
The authors’ participatory process supports that message. Contributors from diverse sectors helped shape the conclusions through workshops and successive drafts, which is consistent with the One Health reality of antimicrobial resistance. Bacteria do not respect sector boundaries, and surveillance cannot succeed if it is boxed into a single institutional silo.
Data Only Matter If They Change Decisions
Surveillance gains become meaningful when they translate into policy, prescribing practice, and resource allocation. The synthesis repeatedly returns to the idea that surveillance should be tied to action. That means the system has to be trusted by decision-makers and usable by the people expected to act on it.
When AMR surveillance is too broad, too slow, or too disconnected from implementation, it becomes an archive rather than a tool. When it is focused, affordable, and embedded in national systems, it can guide stewardship, laboratory investment, and outbreak preparedness. The paper’s emphasis on targeted and cost-effective investments reflects that logic: the goal is not surveillance for its own sake, but surveillance that changes what health systems do next.
A second short truth follows from that premise. Data that do not reach the right hands do not protect patients.
The Next Phase Depends on Sustaining Gains Without Expanding Waste
The conclusion is not that more money alone will solve the AMR problem. It is that funding must be better designed. Expanded domestic public financing, private sector participation, and multilateral support all appear necessary, but none will be enough if investments are spread too thin or directed toward systems that are difficult to maintain. Future AMR surveillance will need planning within resource constraints, a narrower focus where needed, and financing that supports country-led sustainability rather than temporary scale.
That framing is especially important for low- and middle-income countries, where the pressure to do everything at once can produce fragile systems with impressive ambition and limited longevity. The paper favors a more disciplined approach: preserve what already works, refine what is inefficient, and invest where the return in action is highest.
The remaining question is not whether AMR surveillance matters. It does. The harder question is whether governments and partners will fund it in a way that keeps it useful after the next round of external support fades.